Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Overall Health Care Cost During the Year Following Diagnosis of Colorectal Cancer Stratified by History of Colorectal Evaluative Procedures

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The cost-effectiveness of colorectal screening has been modeled; however, the cost of health care following the diagnosis of colorectal cancer has not been described stratified by history of colorectal evaluative procedures.

          Methods

          We identified persons with first diagnosis of colorectal cancer between 2015 and 2017 from the Ontario Cancer Registry, and categorized them by history of colorectal evaluative procedures during Period 1 (the 10 years before the 6-month prediagnostic interval) with or without procedures during Period 2 (the 6 month prediagnostic interval), versus only during Period 2, versus none. We extracted overall health care cost 1 year following diagnosis from population-wide administrative databases.

          Results

          Among cases diagnosed at 52 to 74 years, overall health care cost among those with no colorectal evaluative procedures on or before the date of diagnosis is $71,039.65 (SD $51,825.18), compared to $48,406.15 (SD $38,843.64) among those who received colorectal evaluative procedures during Period 1, with or without procedures during Period 2. Among the population aged 20 to 74 years at diagnosis, cases with ≥1 screening colonoscopies for hereditary CRC syndrome, the mean overall initial cost was between $32,300.32 (SD) and $33,084.67 (SD $39,905.77), and those with ≥1 screening colonoscopies because of a first-degree relative with CRC, was between $36,344.71 (SD $35,539.85) and $45,456.41 (SD $49,818.59).

          Conclusions

          Overall health care cost is lower among cases who received colorectal evaluative procedures during Period 1, with or without procedures during Period 2, and among those with screening colonoscopy for hereditary CRC syndromes or affected first-degree relatives.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Phase-specific and lifetime costs of cancer care in Ontario, Canada

          Background Cancer is a major public health issue and represents a significant economic burden to health care systems worldwide. The objective of this analysis was to estimate phase-specific, 5-year and lifetime net costs for the 21 most prevalent cancer sites, and remaining tumour sites combined, in Ontario, Canada. Methods We selected all adult patients diagnosed with a primary cancer between 1997 and 2007, with valid ICD-O site and histology codes, and who survived 30 days or more after diagnosis, from the Ontario Cancer Registry (N = 394,092). Patients were linked to treatment data from Cancer Care Ontario and administrative health care databases at the Institute for Clinical and Evaluative Sciences. Net costs (i.e., cost difference between patients and matched non-cancer control subjects) were estimated by phase of care and sex, and used to estimate 5-year and lifetime costs. Results Mean net costs of care (2009 CAD) were highest in the initial (6 months post-diagnosis) and terminal (12 months pre-death) phases, and lowest in the (3 months) pre-diagnosis and continuing phases of care. Phase-specific net costs were generally lowest for melanoma and highest for brain cancer. Mean 5-year net costs varied from less than $25,000 for melanoma, thyroid and testicular cancers to more than $60,000 for multiple myeloma and leukemia. Lifetime costs ranged from less than $55,000 for lung and liver cancers to over $110,000 for leukemia, multiple myeloma, lymphoma and breast cancer. Conclusions Costs of cancer care are substantial and vary by cancer site, phase of care and time horizon analyzed. These cost estimates are valuable to decision makers to understand the economic burden of cancer care and may be useful inputs to researchers undertaking cancer-related economic evaluations. Electronic supplementary material The online version of this article (doi:10.1186/s12885-016-2835-7) contains supplementary material, which is available to authorized users.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical Practice Guideline on Screening for Colorectal Cancer in Individuals With a Family History of Nonhereditary Colorectal Cancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus

            A family history (FH) of colorectal cancer (CRC) increases the risk of developing CRC. These consensus recommendations developed by the Canadian Association of Gastroenterology and endorsed by the American Gastroenterological Association, aim to provide guidance on screening these high-risk individuals.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: Guidelines on colon cancer screening.

                Bookmark

                Author and article information

                Journal
                J Can Assoc Gastroenterol
                J Can Assoc Gastroenterol
                jcag
                Journal of the Canadian Association of Gastroenterology
                Oxford University Press (US )
                2515-2084
                2515-2092
                December 2021
                06 March 2021
                06 March 2021
                : 4
                : 6
                : 274-283
                Affiliations
                [1 ] Institute for Healthcare Policy, Management, and Evaluation, University of Toronto , Toronto, Ontario, Canada
                [2 ] Cancer Research Program, ICES , Toronto, Ontario, Canada
                Author notes
                Correspondence: Lawrence Paszat, BA, MD, MS, FRCPC, University of Toronto, Sunnybrook Health Sciences Centre, T2-156 2075 Bayview Avenue, Toronto, Ontario M4N3M5 Canada, e-mail: lawrence.paszat@ 123456sunnybrook.ca
                Author information
                https://orcid.org/0000-0002-3595-1493
                https://orcid.org/0000-0002-0264-2176
                Article
                gwab001
                10.1093/jcag/gwab001
                8643617
                34877466
                c926ff41-f53b-4e0c-ae2a-d6ac7ccc700e
                © The Author(s) 2021. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 05 August 2020
                : 01 February 2021
                Page count
                Pages: 10
                Funding
                Funded by: Cancer Care Ontario, DOI 10.13039/100009142;
                Categories
                Original Articles
                AcademicSubjects/MED00260

                colonoscopy,colorectal cancer,fecal occult blood testing,health care costs

                Comments

                Comment on this article